Skip to main navigation

Home
News & Presentations
Governance
Financials
Stock Information
Resources

News Releases

News Releases

Year

Nov 23, 2020

Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis

Nov 11, 2020

Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Nov 05, 2020

Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update

Nov 04, 2020

Arcutis Announces Appointment of Terrie Curran to Board of Directors

Nov 02, 2020

Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis

Oct 29, 2020

Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences

Oct 26, 2020

Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

Oct 06, 2020

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

Oct 01, 2020

Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock

Sep 29, 2020

Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Displaying 1 - 10 of 42

Print Page

RSS Feeds

Email Alerts

Search

information@arcutis.com

linkedin

Who We Are
Our Focus
Pipeline
Clinical Trials
Investors
Contact
News / Press
Legal Disclaimer

© 2020 Arcutis Biotherapeutics